News

“NATICK, Mass.–(BUSINESS WIRE)–Naveris, a healthcare company dedicated to improving patient care through early detection of virus-related cancers, today announced the close of its expanded Series A financing, bringing the total raised to over $19 million since the company’s inception. Gurnet Point Capital (GPC), a private investment fund focused in the healthcare and life sciences sector, led the financing round.” Read the full article at BusinessWire.

“WALTHAM, Mass.–(BUSINESS WIRE)–A novel blood test can detect recurrent Human Papilloma Virus (HPV)-related head and neck (oropharyngeal) cancers, according to a study published online in the Journal of Clinical Oncology by researchers at the University of North Carolina School of Medicine. The multi-year, prospective study underscores the test’s potential to allow patients with recurrent disease to begin earlier treatment and spare disease-free patients from repeated invasive testing.” Read the full article on BusinessWire.com.

Liquid biopsy test confirms remission in HPV-associated oral cancer October 24, 2018 A novel liquid biopsy test showed compelling specificity and sensitivity in detecting HPV DNA among patients who underwent chemoradiotherapy for HPV-associated oropharyngeal squamous cell carcinoma, according to findings presented at the American Society for Radiation Oncology Annual Meeting. “This blood test has exceptional performance in monitoring patients for cancer recurrence after radiation therapy,” Bhisham Chera, MD, an associate professor of radiation oncology at The University of North Carolina…

Blood Test Confirms Remission in HPV-Associated Oral Cancer Patients 25 Oct 2018 Dentistry Today   UNC Lineberger’s Bhishamjit S. Chera, MD, and Gaorav Gupta, MD, PhD. A highly sensitive blood test that detects minute traces of cancer-specific DNA has been shown to accurately determine whether patients with HPV-related oropharyngeal squamous cell carcinoma (OPSCC) are free from cancer following radiation therapy, according to researchers at the University of North Carolina (UNC) at Chapel Hill. The liquid biopsy test, which measures fragments…

Liquid Biopsy Confirms Remission in HPV Oropharyngeal Cancer Roxanne Nelson, BSN, RN October 24, 2018 The so-called liquid biopsy holds great promise for detecting a variety of cancers more accurately, guiding individualized therapy, and improving monitoring during treatment. New data suggest that testing for plasma circulating tumor human papillomavirus DNA (ctHPVDNA) can be an effective method of surveillance for patients with p16-positive oropharyngeal squamous cell carcinoma (OPSCC). The performance of an optimized multianalyte ctHPVDNA blood test for detecting cancer recurrence was “exceptional,”…